Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct;130 Suppl 1(Suppl 1):S41-3.
doi: 10.1016/j.thromres.2012.08.271.

What did we learn from new oral anticoagulant treatment?

Charles T Esmon  1
Affiliations
Review

What did we learn from new oral anticoagulant treatment?

Charles T Esmon. Thromb Res. 2012 Oct.

Abstract

Orally active direct inhibitors of thrombin and factor Xa have now been approved for treatment or prevention of deep vein thrombosis,and stroke associated with atrial fibrillation. The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication. These agents share a rapid onset and are cleared with half lives of approximately 10 hours. At present there is no approved antidote for either class of anticoagulant, making the treatment of life-threatening bleeding episodes problematic. These agents have fewer drug interactions than warfarin, have a predictable clearance, and hence do not require monitoring. Patients with renal insufficiency have delayed clearance and hence may have elevated levels of the drug leading to increased risk of bleeding.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Many targets for new anticoagulants. TF/VIIa, tissue factor/factor VIIa; Xa, factor Xa; IIa, thrombin. Content adapted from Weitz and Bates [19].
See this image and copyright information in PMC

References

    1. Leung LLK. Anticoagulants other than heparin and warfarin. In: Mannucci PM, Landaw SA, Basow DS, editors. UpToDate. UpToDate; Waltham, MA: 2012. Available from http://www.uptodate.com/contents/anticoagulants-other-than-heparin-and-w....
    1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523–32. - PubMed
    1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–91. - PMC - PubMed
    1. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost. 2003;1:1258–63. - PubMed
    1. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood. 2011;118:6667–74. - PubMed

Publication types

MeSH terms